MedTrace Logo

Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients

NCT01957839 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2013-10-08

No results posted yet for this study

Summary

the investigators examined the hypothesis that hyperprolactinemia may alter uterin, endometrial and intraovarian blood flow and may contribute to increased infertility by another way.

Conditions

  • Adverse Reaction to Other Drugs and Medicines

Interventions

DRUG

cabergoline treatment

cabergoline treatment for hyperprolactinemia group

Sponsors & Collaborators

  • Istanbul Bakirkoy Maternity and Children Diseases Hospital

    lead OTHER_GOV

Principal Investigators

  • Osman Temizkan, M.D. · SİSLİ ETFAL TEACHİNG HOSPİTAL

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-08-31
Completion
2011-09-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01957839 on ClinicalTrials.gov